ATR inhibitor

DRUG CLASS:

ATR inhibitor

News alerts, weekly reports and conference planners

Related drugs:

DDR	Cervical Cancer	DDR	Cervical Cancer	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2
ATM deletion	Solid Tumor	ATM deletion	Solid Tumor	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2
ATM deletion	Colorectal Cancer	ATM deletion	Colorectal Cancer	M6620 Sensitive: C3 – Early Trials M6620 Sensitive : C3	M6620 Sensitive: C3 – Early Trials M6620 Sensitive : C3
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
ATM expression + ATM T2333fs* + EGFR negative	HER2 Negative Breast Cancer	ATM expression + ATM T2333fs* + EGFR negative	HER2 Negative Breast Cancer	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
ATM PI2629fs*	Endometrial Cancer	ATM PI2629fs*	Endometrial Cancer	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	QL-VIII-58 Sensitive: C3 – Early Trials QL-VIII-58 Sensitive : C3	QL-VIII-58 Sensitive: C3 – Early Trials QL-VIII-58 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	M6620 Sensitive: C3 – Early Trials M6620 Sensitive : C3	M6620 Sensitive: C3 – Early Trials M6620 Sensitive : C3
NRAS mutation	Melanoma	NRAS mutation	Melanoma	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3
NF1 mutation	Colorectal Cancer	NF1 mutation	Colorectal Cancer	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3
ARID1A mutation	Solid Tumor	ARID1A mutation	Solid Tumor	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3
ATM mutation	Ovarian Cancer	ATM mutation	Ovarian Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	durvalumab + AZD6738 Sensitive: C3 – Early Trials durvalumab + AZD6738 Sensitive : C3	durvalumab + AZD6738 Sensitive: C3 – Early Trials durvalumab + AZD6738 Sensitive : C3
DDR	Ovarian Cancer	DDR	Ovarian Cancer	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
TP53 mutation	Gastric Cancer	TP53 mutation	Gastric Cancer	M6620 Sensitive: C3 – Early Trials M6620 Sensitive : C3	M6620 Sensitive: C3 – Early Trials M6620 Sensitive : C3
TP53 mutation	Gastroesophageal Junction Adenocarcinoma	TP53 mutation	Gastroesophageal Junction Adenocarcinoma	M6620 Sensitive: C3 – Early Trials M6620 Sensitive : C3	M6620 Sensitive: C3 – Early Trials M6620 Sensitive : C3
CHEK2 mutation	Tongue Carcinoma	CHEK2 mutation	Tongue Carcinoma	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4
ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4
FGFR1-G3BP2 fusion	Pancreatic Cancer	FGFR1-G3BP2 fusion	Pancreatic Cancer	BAY 1895344 Resistant: C4 – Case Studies BAY 1895344 Resistant : C4	BAY 1895344 Resistant: C4 – Case Studies BAY 1895344 Resistant : C4
PGBD5 overexpression	Neuroblastoma	PGBD5 overexpression	Neuroblastoma	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D
PGBD5 underexpression	Neuroblastoma	PGBD5 underexpression	Neuroblastoma	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D
TP53 mutation + Chr del(11q)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(11q)	Chronic Lymphocytic Leukemia	ATR inhibitor Sensitive: D – Preclinical ATR inhibitor Sensitive : D	ATR inhibitor Sensitive: D – Preclinical ATR inhibitor Sensitive : D
IDH1 R132H	Glioma	IDH1 R132H	Glioma	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D
ARID1A 548fs	Ovarian Cancer	ARID1A 548fs	Ovarian Cancer	M6620 Sensitive: D – Preclinical M6620 Sensitive : D	M6620 Sensitive: D – Preclinical M6620 Sensitive : D
BRAF V600	Melanoma	BRAF V600	Melanoma	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D
BRAF V600	Melanoma	BRAF V600	Melanoma	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D
ARID1A 756fs	Ovarian Cancer	ARID1A 756fs	Ovarian Cancer	VE-821 Sensitive: D – Preclinical VE-821 Sensitive : D	VE-821 Sensitive: D – Preclinical VE-821 Sensitive : D

ATR inhibitor

ATR inhibitor

Associations(61)

Associations
(61)